. . . . . . . "[Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 � 3.6 months for 'low' and 8.4 � 2.7 months for 'high' expressed group, p<0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 � 2.8 months for 'low' and 9.8 � 1.1 months for 'high' expressed group, p<0.0001).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:27+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .